Researchers are investigating whether the existing vaccines could be used ‘more flexibly’ in the fight against the coronavirus pandemic.
A UK study of the use of different COVID-19 vaccines in two-dose vaccination is being expanded to include injections by Moderna and Novavax, the researchers said. the researchers said.
The trial, known as the Com-Cov study, was first launched in February to see whether giving the first dose of one COVID-19 and a second dose of the other produced an immune response. translation as good as when using two noses. dosage of the same vaccine.
Matthew Snape, a professor at the University of Oxford, who led the experiment, said the idea “was to explore whether the variety of COVID-19 vaccines available could be used more flexibly.
The UK and many other countries in Europe are currently using the Oxford-AstraZeneca and Pfizer-BioNTech COVID vaccines in nationwide immunization campaigns against the coronavirus pandemic.
But reports of blood clots are so rare that some governments – including France and Germany – say that Oxford-AstraZeneca should only be given to certain age groups or those who have already taken the vaccine. AstraZeneca should first switch to another one for their second dose.
During a press conference on research expansion to include Moderna and Novavax’s COVID-19 vaccines, Snape, associate professor of pediatrics and immunization at Oxford, said it would seek to recruit these adults. 50 years old have had their first vaccine, or ”shot, in the past 8-12 weeks.
These volunteers, who were vaccinated against Oxford-AstraZeneca or Pfizer-BioNTech, will be randomly assigned to inject the same vaccine or a Moderna or Novavax vaccine for the second dose.
Snape said the test’s six new weapons will involve 175 people, adding a total of 1,050 recruits.
“If we can demonstrate that these mixed schedules produce as good an immune response as the standard schedule and do not have a significant increase in vaccine response, then this has the potential to allow for more people complete their COVID-19 vaccination course faster, ”said Snape.
“This will also create resilience in the system in the event of a supply shortage of any vaccine”.
Results from the initial blending trial, using only injections of Oxford-AstraZeneca and Pfizer-BioNTech, are expected as early as April or May, while phase two results will arrive in July. .